Drugs / Clade C gp140
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03307915 | Mar 2018 → Nov 2021 | HIV infectious disease | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1 | NCT02685020 | Mar 2016 → Jan 2018 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02935686 | Mar 2017 → Nov 2023 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT02788045 | Jul 2016 → Apr 2022 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03060629 | Nov 2017 → Feb 2022 | — | Janssen Vaccines & Prevention B.V. | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-08-31 | Janssen Research & Development, LLC | Results Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa jnj.com ↗
Data showed the investigational HIV vaccine regimen did not provide sufficient protection against HIV infection in a population of young women in sub-Saharan Africa at high risk of acquiring HIV. |
| 2019-07-23 | Janssen Research & Development, LLC | Results Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen jnj.com ↗
In the study, both regimens induced high immune responses against a broad range of HIV-1 subtypes. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-08-31 | Janssen Research & Development, LLC | Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa jnj.com ↗ |
| 2019-07-23 | Janssen Research & Development, LLC | Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen jnj.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clade C gp140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03307915 ↗ |
| Known as | Clade C Glycoprotein (gp)140 | “Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus...” NCT02685020 ↗ |
| Modality | Vaccine | “The Clade C gp140 vaccine containing 250 mcg of total protein” NCT02685020 ↗ |
| Route | Intramuscular | “All study interventions were administered intramuscularly.” PMID 32078815 ↗ Feb 2020 |